GSK Buys Nuvalent for $10.6 Billion in Massive Cancer Drug Bet
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
/ 18 items
#GSK↓
Myriad Genetics Scores FDA Nod for MyChoice CDx – The Only Approved HRD Test Guiding Zejula Therapy
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.
Upstream Bio's Asthma Drug Hits Goal but Misses Top Hopes
Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.
FDA Rejects Moderna's mRNA Flu Vaccine Application
FDA refuses to review Moderna's innovative mRNA flu vaccine over clinical trial design concerns, sending shares down 7%. Company disputes decision citing prior agency approval.
GSK Acquires RAPT Therapeutics for $2.2 Billion to Develop New Food Allergy Treatment
GSK purchases RAPT Therapeutics for $2.2B, gaining ozureprubart - a promising food allergy treatment requiring injections every 12 weeks instead of every 2 weeks.
GSK and Ionis Announce Major Win Against Hepatitis B in Landmark Trials
GSK and Ionis announce breakthrough results for bepirovirsen, a potential first-in-class treatment offering functional cure for chronic hepatitis B in just six months.